A 40-week trial presented at ADA's 85th Scientific Sessions showed that daily oral orforglipron significantly lowered blood sugar and body weight in adults with early type 2 diabetes.
FDA approves Ekterly (sebetralstat), the first oral on-demand treatment for hereditary angioedema, shown in trials to provide faster symptom relief and eliminate the need for injection.
Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
GAMMAGARD LIQUID ERC is the first ready-to-use liquid immunoglobulin therapy with IgA ≤2 µg/mL for primary immunodeficiency in individuals aged 2 years and older.
The FDA has approved dupilumab as the first targeted treatment for adults with bullous pemphigoid, showing improved remission rates and reduced corticosteroid use.